2000
Founded;
-
-
2003Jitai® (Thymalfasin for Injection) approved and launched in China
-
2004~2009Sales maintained increasing by 50%;
-
2010Acquired Hainan Weile Pharmaceuticals Co., Ltd;
-
2012Initial public offering in 2012;
-
2013Passed USFDA GMP inspection for peptide API facility;
-
2014Establised holding subsidiary in Ningbo;
-
2016Passed USFDA unannounced GMP inspection;Passed EMA on-site inspection for sterile drug product Thymalfasin FDA & API;
-
2017Received Italian MA decree for Thymalfasin for Injecion;Passed the USFDA PAI for Bivalirudin API & FDF;
-
2018Received USFDA tentative approval for Bivalirudin for Injection;
Submitted quality consistency evaluation of Thymalfasin for Injection to NMPA; -
2019US FDA unannounced GMP inspection;Successfully challenged the patent of RLD of Bivalirudin for Injection and received US FDA final approval;Received US FDA approval for Pregabalin Capsule;Passed the US FDA PAI for memantine Hydrochloride Tablets
-
2020Received US FDA MA approval for Memantine Hydrochloride Tablets;Exported Bivalirudin for Injection to US
